[Comparative efficacy and safety of antidepressant mono- and multimodal therapy in elderly patients with depression (a clinical experience in a psychogeriatric hospital)].

Kalyn IaB, Safarova TP, Sheshenin VC, Gavrilova SI

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2014Cited by 2 (Europe PMC)

PMID25042499PepBankPUB-25042499

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In elderly patients with depression, cerebrolysin added to venlafaxine produced a faster response than venlafaxine alone.
In plain wordsIn elderly patients with depression, cerebrolysin plus venlafaxine produced a faster response than venlafaxine alone.
Peptide
Cerebrolysin
Outcome
DecreaseTime to therapeutic response
Study
n = 40
Comparator
Venlafaxine monotherapy
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
20.0 ml · intravenous infusionAs given in this study (human).
Source sentences
Summary
However, the use of multimodal therapy allowed to get the more rapid response and more pronounced therapeutic effect compared to monotherapy with the same antidepressant, as well as to reduce adverse events.
3 context sentences(design, population, supporting numbers)
Summary · context
Two groups of patients (20 patients in each group), aged 60 years and older (60 to 79 years), were studied.
Summary · context
The groups were matched for demographic and clinical (severity of depressive episode) characteristics.
Summary · context
Patients of the second group received additionally 20 intravenous infusions of cerebrolysin (20.0 ml in 100 ml isotonic sodium chloride solution).
Report a problemFND-2504249904
02HumanNon-randomized trialEfficacy outcome
In elderly patients with depression, cerebrolysin added to venlafaxine produced a more pronounced therapeutic effect than venlafaxine alone.
In plain wordsIn elderly patients with depression, cerebrolysin plus venlafaxine produced a greater therapeutic effect than venlafaxine alone.
Peptide
Cerebrolysin
Outcome
IncreaseTherapeutic effect
Study
n = 40
Comparator
Venlafaxine monotherapy
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
20.0 ml · intravenous infusionAs given in this study (human).
Source sentences
Summary
However, the use of multimodal therapy allowed to get the more rapid response and more pronounced therapeutic effect compared to monotherapy with the same antidepressant, as well as to reduce adverse events.
3 context sentences(design, population, supporting numbers)
Summary · context
Two groups of patients (20 patients in each group), aged 60 years and older (60 to 79 years), were studied.
Summary · context
The groups were matched for demographic and clinical (severity of depressive episode) characteristics.
Summary · context
Patients of the second group received additionally 20 intravenous infusions of cerebrolysin (20.0 ml in 100 ml isotonic sodium chloride solution).
Report a problemFND-2504249905
03HumanNon-randomized trialSafety outcome
In elderly patients with depression, cerebrolysin added to venlafaxine reduced adverse events compared with venlafaxine alone.
In plain wordsIn elderly patients with depression, cerebrolysin plus venlafaxine reduced adverse events compared with venlafaxine alone.
Peptide
Cerebrolysin
Outcome
DecreaseAdverse events
Study
n = 40
Comparator
Venlafaxine monotherapy
Outcome group
Adverse events · Whole body
Studied dose
20.0 ml · intravenous infusionAs given in this study (human).
Source sentences
Summary
However, the use of multimodal therapy allowed to get the more rapid response and more pronounced therapeutic effect compared to monotherapy with the same antidepressant, as well as to reduce adverse events.
3 context sentences(design, population, supporting numbers)
Summary · context
Two groups of patients (20 patients in each group), aged 60 years and older (60 to 79 years), were studied.
Summary · context
The groups were matched for demographic and clinical (severity of depressive episode) characteristics.
Summary · context
Patients of the second group received additionally 20 intravenous infusions of cerebrolysin (20.0 ml in 100 ml isotonic sodium chloride solution).
Report a problemFND-2504249906

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

04HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome
In elderly patients with depression, venlafaxine with or without cerebrolysin showed a good balanced therapeutic profile for symptoms of depression, anxiety and apathy.
In plain wordsIn elderly patients, venlafaxine with or without cerebrolysin showed a good balanced profile for depression, anxiety and apathy symptoms.
Peptide
Cerebrolysin
Outcome
Direction not reportedDepression, anxiety and apathy symptoms
Study
n = 40
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
Therapeutic effect of antidepressant therapy (56 days) was characterized by a good balanced profile in relation to symptoms of depression, anxiety and apathy in both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Two groups of patients (20 patients in each group), aged 60 years and older (60 to 79 years), were studied.
Summary · context
The groups were matched for demographic and clinical (severity of depressive episode) characteristics.
Summary · context
Patients of the second group received additionally 20 intravenous infusions of cerebrolysin (20.0 ml in 100 ml isotonic sodium chloride solution).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2504249901

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.